News
- Author:
- Andrew D. Bowser
Publish date: October 15, 2019
Results of phase 2 study show improvements in histologic, endoscopic, and patient-reported dysphagia outcome measures.
News
- Author:
- Andrew D. Bowser
Publish date: October 9, 2019
Thrombocytopenia with anemia should alert physicians to this possible rare diagnosis in older patients with nonspecific neurological abnormalities....
News
- Author:
- Andrew D. Bowser
Publish date: October 1, 2019
PHILADELPHIA – No difference with traditional intent-to-treat analysis, but heart failure hospitalizations were c...
Article
- Author:
- Andrew D. Bowser
Publish date: September 29, 2019
PHILADELPHIA – The findings support monitoring of cardiac biomarkers in the initial phase of checkpoint inhibitor treatment to identify patients at...
News
- Author:
- Andrew D. Bowser
Publish date: September 22, 2019
Highest WATCH-DM scores linked to 5-year heart failure risk approaching 20%.
News
- Author:
- Andrew D. Bowser
Publish date: September 16, 2019
PHILADELPHIA – Survival benefit favored milrinone regardless of indication for use in continuous outpatient intravenous inotropic therapy.
News
- Author:
- Andrew D. Bowser
Publish date: September 4, 2019
ALEXANDRIA, VA. – Access to promising agents, enhanced supportive care, or both could provide direct patient benefit.
News
- Author:
- Andrew D. Bowser
Publish date: September 4, 2019
ALEXANDRIA, VA. – If confirmed in a nationally representative study, findings could have implications for health policy and oncology practice.
News
- Author:
- Andrew D. Bowser
Publish date: September 3, 2019
The pan-ErbB inhibitor pyrotinib plus capecitabine had manageable toxicity, a significantly higher ORR, and significantly longer PFS, compared with...
News
- Author:
- Andrew D. Bowser
Publish date: August 29, 2019
Strategy incorporating protease inhibitor nelfinavir yields promising efficacy, acceptable toxicity in locally advanced non–small cell lung cancer....
News
- Author:
- Andrew D. Bowser
Publish date: August 26, 2019
ODYSSEY OUTCOMES analyses peg prior CABG and polyvascular disease as targets for alirocumab.
News
- Author:
- Andrew D. Bowser
Publish date: August 26, 2019
Fewer sites of disease and lower intratumor heterogeneity on contrast-enhanced CT may indicate a higher likelihood of durable response to immune ch...
News
- Author:
- Andrew D. Bowser
Publish date: August 20, 2019
In data that complement the TAILORx findings, chemotherapy was not linked with significantly improved OS for those with a low recurrence score amon...
News
- Author:
- Andrew D. Bowser
Publish date: August 20, 2019
Personal cancer history, ancestry now key factors in decision to assess, counsel, and test for potentially harmful mutations in BRCA1/2 genes.
News
- Author:
- Andrew D. Bowser
Publish date: August 19, 2019
By contrast, antiplatelet therapy linked to reduced risk of stroke, whether or not oral anticoagulation was used in this PARTNER II substudy.
